Sustained release of ubiquitin-like protein ISG-15 enhances tendon-to-bone healing following anterior cruciate ligament reconstruction in a mouse model.
IF 4.3 3区 工程技术Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Jun-Cheng Yao, Jie-Xin Zhang, Xuan Wang, Yu-Hao Wu, Hao-Lin Ke, Jia-Rong Liang, Yan Shao, Jin-Tao Li, Yuan Liu, Dao-Zhang Cai, Jian-Ying Pan
{"title":"Sustained release of ubiquitin-like protein ISG-15 enhances tendon-to-bone healing following anterior cruciate ligament reconstruction in a mouse model.","authors":"Jun-Cheng Yao, Jie-Xin Zhang, Xuan Wang, Yu-Hao Wu, Hao-Lin Ke, Jia-Rong Liang, Yan Shao, Jin-Tao Li, Yuan Liu, Dao-Zhang Cai, Jian-Ying Pan","doi":"10.3389/fbioe.2025.1550584","DOIUrl":null,"url":null,"abstract":"<p><p>The process of tendon-to-bone healing is regulated by several proteins and cytokines that play critical roles in shaping biomechanical properties and functional recovery. Among these, the ubiquitin-like protein ISG-15 has been reported to have a beneficial effect on tissue repair. However, its specific function in tendon-to-bone interface regeneration has not been well characterized. This study investigated the function of ISG15 <i>in vitro</i> and addressed its <i>in vivo</i> effects on tendon and bone healing. In this study, wild-type C57/BL6 mice underwent anterior cruciate ligament (ACL) reconstruction surgery, with a sustained-release hydrogel containing ISG15 protein injected into the bone tunnels in the treatment group. To assess its therapeutic potential, bone-tendon interface growth was evaluated through histological staining, while micro-computed tomography (Micro-CT) was employed to quantify newly formed bone and bone density within the bone tunnels. Additionally, biomechanical testing was performed to measure the mechanical strength of the grafted tendons, and immunohistochemistry was conducted to detect the expression of Runx2 and osteocalcin (OCN) at the bone-tendon interface. <i>In vitro</i> results showed that an appropriate concentration of ISG-15 has the ability to promote osteogenic differentiation of bone marrow mesenchymal stem cells. Also, In the <i>in vivo</i> experiments, the local application of ISG15 protein significantly reduced inflammatory tissue growth during the early stages of healing and minimized bone resorption in the later stages. Furthermore, Micro-CT analysis showed an increased volume of newly formed bone in the treatment group, while biomechanical testing demonstrated enhanced mechanical strength of the grafted tendons. In summary, this study suggests that the localized sustained release of ISG15 protein during ACL reconstruction facilitates tendon-to-bone interface repair by promoting bone ingrowth, ultimately leading to improved biomechanical properties and functional recovery.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1550584"},"PeriodicalIF":4.3000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937028/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1550584","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The process of tendon-to-bone healing is regulated by several proteins and cytokines that play critical roles in shaping biomechanical properties and functional recovery. Among these, the ubiquitin-like protein ISG-15 has been reported to have a beneficial effect on tissue repair. However, its specific function in tendon-to-bone interface regeneration has not been well characterized. This study investigated the function of ISG15 in vitro and addressed its in vivo effects on tendon and bone healing. In this study, wild-type C57/BL6 mice underwent anterior cruciate ligament (ACL) reconstruction surgery, with a sustained-release hydrogel containing ISG15 protein injected into the bone tunnels in the treatment group. To assess its therapeutic potential, bone-tendon interface growth was evaluated through histological staining, while micro-computed tomography (Micro-CT) was employed to quantify newly formed bone and bone density within the bone tunnels. Additionally, biomechanical testing was performed to measure the mechanical strength of the grafted tendons, and immunohistochemistry was conducted to detect the expression of Runx2 and osteocalcin (OCN) at the bone-tendon interface. In vitro results showed that an appropriate concentration of ISG-15 has the ability to promote osteogenic differentiation of bone marrow mesenchymal stem cells. Also, In the in vivo experiments, the local application of ISG15 protein significantly reduced inflammatory tissue growth during the early stages of healing and minimized bone resorption in the later stages. Furthermore, Micro-CT analysis showed an increased volume of newly formed bone in the treatment group, while biomechanical testing demonstrated enhanced mechanical strength of the grafted tendons. In summary, this study suggests that the localized sustained release of ISG15 protein during ACL reconstruction facilitates tendon-to-bone interface repair by promoting bone ingrowth, ultimately leading to improved biomechanical properties and functional recovery.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.